

1 **(Brief report)**

2 **Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2**

3 **B.1.1.529 (Omicron) variant of concern**

4

5 Kevin K. Ariën<sup>1,2,\*</sup>, Leo Heyndrickx<sup>1</sup>, Johan Michiels<sup>1</sup>, Katleen Vereecken<sup>1</sup>, Kurt Van Lent<sup>3</sup>, Sandra  
6 Coppens<sup>1</sup>, Pieter Pannus<sup>4</sup>, Geert A. Martens<sup>5</sup>, Marjan Van Esbroeck<sup>3</sup>, Maria E. Goossens<sup>4</sup>, Arnaud  
7 Marchant<sup>6</sup>, Koen Bartholomeeusen<sup>1</sup>, Isabelle Desombere<sup>7</sup>

8

9 <sup>1</sup>Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp,  
10 Belgium

11 <sup>2</sup> Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

12 <sup>3</sup> Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium

13 <sup>4</sup> SD Epidemiology and Public Health, Sciensano, Brussels, Belgium

14 <sup>5</sup> Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium

15 <sup>6</sup> Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université  
16 libre de Bruxelles (ULB), Gosselies, Belgium

17 <sup>7</sup> Immune response, SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium

18 \*correspondence: [karien@itg.be](mailto:karien@itg.be)

19 **Abstract**

20 We report the levels of neutralising antibodies against Wuhan, Delta and Omicron variants in healthy  
21 individuals pre-infected or not with SARS-CoV-2 and immunized with three doses of the BNT162b2  
22 vaccine. Our observations support the rapid administration of a booster vaccine dose to prevent  
23 infection and disease caused by Omicron.

24

25 **Introduction**

26 Researchers in Botswana and South Africa identified a new and heavily mutated SARS-CoV-2 variant  
27 (B.1.1.529, Omicron) in late November 2021, with 30 amino acid mutations in the Spike protein that  
28 are distinct compared to other variants of concern (VOC) Alpha, Beta and Delta [1]. Omicron is  
29 characterized by fast spreading in previously vaccinated populations, suggesting Omicron's ability to  
30 evade vaccine-induced immunity [2] and therapeutic monoclonal antibody therapy [3]. Several  
31 recent pre-print studies have indeed confirmed a substantial reduction in neutralising antibody  
32 activity against Omicron in small-scaled studies including previously infected individuals, fully  
33 vaccinated individuals, recipients of third booster doses of BNT162b2 or mRNA-1273 and individuals  
34 with hybrid immunity (infection followed by vaccination) [4-9]. The common trend from these first  
35 laboratory-based assessments is that the potency to neutralise Omicron is reduced by approximately  
36 40-fold (20-200-fold depending on the study) compared to the original Wuhan D614G virus.

37 Here, we have assessed the levels of neutralising antibodies (nAb) against the original Wuhan strain,  
38 Delta (B.1.617.2) and Omicron (B.1.1.529) VOC of 30 sera collected from individuals infected with  
39 SARS-CoV-2 prior to vaccination (Group 1), from infection-naïve individuals after three doses of  
40 BNT162b2 (Group 2) and from previously-infected individuals after three doses of BNT162b2 (Group  
41 3).

42

43 **Methods**

44 *Omicron variant isolation and sequence confirmation*

45 An Omicron virus isolate was made from a nasopharyngeal (NP) swab collected from a patient with  
46 sequence-confirmed Omicron infection returning from a stay in the Republic of South Africa. An  
47 additional NP swab was collected 48h after RT-qPCR diagnosis and 24h after sequence confirmation  
48 of infection with the Omicron variant. The patient was infected after a complete course of  
49 vaccination with mRNA-1273 (Moderna) and presented with mild symptoms (cough, sore throat).  
50 The NP swap was collected on universal transport medium (UTM) and transferred fresh to the BSL3  
51 laboratory immediately after collection. Two times 200µl of 1/2 diluted sample and 2x 200µl of 1/4  
52 diluted sample (in Vero cell medium with 2% FBS) were added to a 80-100% confluent layer of Vero  
53 cells plated 1.5h before in 24-well plates in Vero cell medium with 2% FBS (300.000 cells/well, plates  
54 were incubated at 37°C and 7% CO<sub>2</sub> before inoculation). Cells were spinoculated for 30 min. at 2500  
55 g and 37°C, then placed again for 10-15 min. in the incubator, after which 800µl of fresh Vero cell  
56 medium with 2% FBS was added. Plates were subsequently incubated at 37° and 7% CO<sub>2</sub> and  
57 cytopathogenic effect (CPE) was scored daily by microscopy. On day 4 post inoculation, CPE was  
58 clearly visible in all inoculated wells and virus supernatant from all 4 wells was collected and pooled.  
59 Virus was further passaged a second time on Vero cells by adding 2 ml of the freshly collected virus  
60 suspension to 95-100% confluent grown Vero cells in a T175 culture flask and incubated for 2h at  
61 37°C and 7% CO<sub>2</sub>. Next, the cells were washed with PBS, 35ml of fresh Vero cell medium with 2% FBS  
62 was added and cells were incubated again at 37° and 7% CO<sub>2</sub>. On day 4 CPE was clearly visible and  
63 virus was collected, centrifuged for 5 min. at 3220 g to remove debris, aliquoted and stored at -80°C.  
64 Sequence confirmation regarding Omicron classification was obtained by sequencing the Spike gene  
65 on passage 1 of the viral isolate. Viral RNA was extracted using the QIAamp viral RNA mini kit  
66 (Qiagen) and the Spike coding sequence was RT-PCR amplified with primer sets COV2-800-39R  
67 (CAAAGGCACGCTAGTAGTCGTC), COV2-800-32L (GGGTGTTGCTATGCCTAATCTTTACA), COV2-800-38R  
68 (TGCAGTAGCGCAACAAAATCT) and COV2-800-33L (TGCATGCAAATTACATATTTTGGAGGA), and  
69 subsequently sequenced with primers COV2-800-34L (GTTGGATGGAAAGTGAGTTCAGAGT), COV2-  
70 800-35L (TTCCGCATCATTTTCCAATTTAAGT), COV2-800-36L (TGACAGAAGTCCCTGTTGCTA), COV2-

71 800-37L (TGCAGATGCTGGCTTCATCAAA), COV2-800-38L (CTTCCCTCAGTCAGCACCTCAT), COV2-800-  
72 32L (GGGTGTTGCTATGCCTAATCTTTACA), COV2-800-39R (CAAAGGCACGCTAGTAGTCGTC), COV2-800-  
73 33L (TGCATGCAAATTACATATTTTGGAGGA), and COV2-800-38R (TGCAGTAGCGCGAACAAAATCT)  
74 (adapted from [10]). Using BLAST+, the obtained Spike sequence was found to be identical to a  
75 recently published SARS-CoV-2 Omicron sequence from Belgium (GenBank accession number  
76 UFO69279.1).

77

#### 78 *SARS-CoV-2 whole-virus neutralisation assay*

79 SARS-CoV-2 neutralising antibodies were quantified as previously reported [11,12]. Briefly, serial  
80 dilutions of heat-inactivated serum (1/50-1/25600 in EMEM supplemented with 2 mM L-glutamine,  
81 100 U/ml-100 µg/ml of Penicillin–Streptomycin and 2% fetal bovine serum) were incubated during 1  
82 h (37 °C, 7% CO<sub>2</sub>) with 3xTCID<sub>50</sub> of wild type (WT) Wuhan strain (2019-nCoV-Italy-INMI1, reference  
83 008 V-03893), 83DJ-1 (B.1.617.2, Delta) or VLD20211207 (B.1.1.529, Omicron). One hundred µl of  
84 sample-virus mixtures and virus/cell controls were added to 100µl of Vero cells (18.000 cells/well) in  
85 a 96-well plate and incubated for five days (37 °C, 7% CO<sub>2</sub>). The CPE caused by viral growth was  
86 scored microscopically. The Reed–Muench method was used to calculate the nAb titer that reduced  
87 the number of infected wells by 50% (NT<sub>50</sub>), which was used as a proxy for the nAb concentration in  
88 the sample. The Mann-Whitney test was used to compare Wuhan and variant nAb titers.

89

#### 90 **Results and discussion**

91 We tested three representative patient groups for neutralising antibody capacity against Wuhan,  
92 Delta and Omicron variants of SARS-CoV-2 in a whole-virus neutralisation assay (Figure 1). Group 1  
93 sera (n=10) were obtained from COVID-19 patients hospitalized with severe infection. All patients  
94 were infected between 24 Feb 2020 and 27 March 2020 when Wuhan D614G was the only variant  
95 circulating and when vaccines were not yet available. Samples tested were collected with a median  
96 time after onset of symptoms of 25 days [range 13-46]. Group 2 sera (n=10) were obtained from

97 individuals without a documented previous SARS-CoV-2 infection and 28 days after third dose of  
98 BNT162b2. All individuals were vaccinated with a 21-day interval between dose 1 and 2 and received  
99 third dose 7 months (median 211 days [207-219]) after dose 2. Group 3 sera (n=10) were obtained  
100 from individuals with hybrid immunity, i.e. individuals who have had a previous infection with Wuhan  
101 D614G between 24 March 2020 and 11 June 2020, followed by three doses of the BNT162b2 vaccine.  
102 Dose 1 and dose 2 were given 21-days apart and the third dose was administered with a median time  
103 interval of 8 months (median 261 days [218-290]) after dose 2.

104  
105 Individuals with immunity after infection but without vaccination (Group 1) have the lowest nAb  
106 responses regardless of the variant tested (Geometric mean titer (GMT)<sub>Wuhan</sub> 1086, GMT<sub>Delta</sub> 151,  
107 GMT<sub>Omicron</sub> <50) (Figure 1). Infection-naïve individuals that received three doses of the BNT162b2  
108 vaccine (Group 2) showed significantly higher nAb levels against Wuhan (GMT<sub>Wuhan</sub> 2157), Delta  
109 (GMT<sub>Delta</sub> 477) and Omicron (GMT<sub>Omicron</sub> 165). Individuals with hybrid immunity (Group 3) showed the  
110 highest NT50 values against Wuhan (GMT<sub>Wuhan</sub> 4822), Delta (GMT<sub>Delta</sub> 1159) and Omicron (GMT<sub>Omicron</sub>  
111 236) variants, but the nAb levels for Omicron were not statistically different between Groups 2 and 3.  
112 We observed a significant reduction in NT50 across the three groups for the Delta variant (Group 1:  
113 7.2 fold reduction; Group 2: 4.5 fold reduction; Group 3: 4.2 fold reduction in GMT) and a  
114 significantly larger reduction against the Omicron variant (Group 1: >22 fold reduction; Group 2: 13.1  
115 fold reduction; Group 3: 20.5 fold reduction in GMT). This drop in nAb titer is most pronounced for  
116 Group 1 (infection/no vaccination), but even for triple vaccinated subjects with (Group 3) or without  
117 (Group 2) previous infection, the NT50<sub>Omicron</sub> is significantly lower than for the Wuhan and Delta  
118 strains. Our data confirm the earlier observation that three doses of the mRNA vaccine BNT162b2  
119 results in high neutralising antibody titers for the three variants tested. Although hybrid immunity  
120 obtained through infection and subsequent vaccination results in significantly higher nAb levels  
121 against Wuhan and Delta, the difference for Omicron is not statistically significant compared to the  
122 3-dose BNT162b2 vaccine schedule.

123 In this study, we analysed only one critical component of immunity to SARS-CoV-2. Non-neutralizing  
124 functions of antibodies and T-cell responses may be less affected by mutations of the Omicron  
125 variant and may thereby provide some compensation to immune escape. While multiple studies,  
126 including ours, have provided evidence that the Omicron variant can escape naturally acquired and  
127 vaccine-induced immune responses, disease severity caused by the variant remains unclear.

128

129 In conclusion, our findings confirm that three doses of the BNT162b2 vaccine confers neutralising  
130 antibody capacity against Omicron, and that vaccine-induced responses (Groups 2 and 3) outperform  
131 naturally-acquired immunity (Group 1). Hybrid immunity (Group 3) results in significantly higher nAb  
132 levels against Wuhan and Delta, but not against Omicron. The observation that a 2-dose schedule of  
133 BNT162b2 is not sufficient to neutralize Omicron [6,7,9] warrants for rapid administration of a  
134 booster vaccine dose to counter infection and limit disease caused by this variant.

135 **Author contributions.** KKA wrote the paper. LH, JM, KV, KVL, SC, PP, MVE and KB conducted  
136 experimental work and data analysis. KKA, AM, ID conceived the study. KKA and MEG were  
137 responsible to obtain the funding. All authors read, edited and approved the final manuscript.

138

139 **Acknowledgements.** We are grateful to Guido Vanham for critically reviewing the manuscript, to  
140 Caroline Rodeghiero and Sarah Houben for logistical and administrative support.

141

142 **Financial support.** This work was supported by the Belgian Federal Government through Sciensano  
143 (COVID-19\_SC004, \_SC049, \_SC059, \_SC103) and the Research Foundation Flanders (FWO  
144 G0G4220N).

145

146 **Potential conflicts of interest.** All authors: No reported conflicts of interest.

147

## 148 **References**

- 149 1. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron  
150 variant in southern Africa. medRxiv 2021.12.19.21268028
- 151 2. Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection  
152 associated with emergence of the Omicron variant in South Africa. medRxiv  
153 2021.11.11.21266068
- 154 3. Aggarwal A, Stella AO, Walker G, et al. SARS-CoV-2 Omicron: evasion of potent humoral  
155 responses and resistance to clinical immunotherapeutics relative to viral variants of concern.  
156 medRxiv 2021.12.14.21267772
- 157 4. Cele S, Jackson L, Khan K, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of  
158 Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection.  
159 medRxiv 2021.12.08.21267417

- 160 5. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron)  
161 evades neutralization by sera from vaccinated and convalescent individuals.  
162 medRxiv 2021.12.08.21267491
- 163 6. Hansen CH, Schelde AB, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2  
164 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or  
165 mRNA-1273 vaccination series: A Danish cohort study. medRxiv 2021.12.20.21267966
- 166 7. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2  
167 Omicron infection. medRxiv 2021.12.13.21267670
- 168 8. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization properties of the SARS-CoV-  
169 2 Omicron variant. medRxiv 2021.12.12.21267646
- 170 9. Lustig Y, Gonen T, Meltzer L, et al. Superior immunogenicity and effectiveness of the 3rd  
171 BNT162b2 vaccine dose. medRxiv 2021.12.19.21268037
- 172 10. Selhorst P, van Ierssel SH, Michiels J, et al. Symptomatic Severe Acute Respiratory Syndrome  
173 Coronavirus 2 Reinfection of a Healthcare Worker in a Belgian Nosocomial Outbreak Despite  
174 Primary Neutralizing Antibody Response. Clin Infect Dis. 2021 Nov 2;73(9):e2985-e2991.
- 175 11. Mariën J, Ceulemans A, Michiels J, et al. Evaluating SARS-CoV-2 spike and nucleocapsid  
176 proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex  
177 bead-based assay. J Virol Methods. 2021 Feb;288:114025
- 178 12. Pannus P, Neven KY, De Craeye S, et al. Poor antibody response to BioNTech/Pfizer COVID-19  
179 vaccination in SARS-CoV-2 naïve residents of nursing homes. Clin Infect Dis. 2021 Dec  
180 3:ciab998



